West Nile Virus

CDC inks licensing agreement for test for WNV

Published in Medical Letter on the CDC and FDA, June 8th, 2003

Spectral Diagnostics, Inc., (SDI) announced the signing of a licensing agreement with the U.S. Centers for Disease Control (CDC) to develop a rapid point-of-care test for West Nile Virus (WNV) infection.

West Nile Virus is spread to humans via mosquitoes and blood transfusion.

Under the licensing agreement, CDC will provide Spectral with reagents, consisting of antibodies, antigens, and scientific support in exchange for future royalties on in-market sales. Spectral plans to utilize its expertise in point-of-care diagnostics to develop a WNV test on its existing STATus platform, as well as its novel finger-prick based microfluidic platforms.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry